Exchange
Nasdaq
Every company in the roster listed on Nasdaq.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
280 of 280 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 AstraZenecaAZN · Nasdaq | 78 assets: 28 approved, 21 Ph 3, 19 Ph 2, 10 Ph 1 | AZD0780Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 19 Oct 2026Benralizumab · Approved |
 SanofiSNY · Nasdaq | 37 assets: 14 approved, 7 Ph 3, 10 Ph 2, 6 Ph 1 | Ciclesonide (XRP1526)Phase 3 · AsthmaReliable signal | 7 Oct 2026dupilumab · Phase 3 |
 AmgenAMGN · Nasdaq | 31 assets: 19 approved, 8 Ph 3, 1 Ph 2, 3 Ph 1 | ABP 938Phase 3 · Age-Related Macular DegenerationReliable signal | 31 Oct 2026Sotorasib · Phase 1 |
 Regeneron PharmaceuticalsREGN · Nasdaq | 31 assets: 6 approved, 8 Ph 3, 14 Ph 2, 3 Ph 1 | itepekimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal | 7 Oct 2026dupilumab · Phase 3 |
 Gilead SciencesGILD · Nasdaq | 20 assets: 9 approved, 6 Ph 3, 4 Ph 2, 1 Ph 1 | AmbrisentanPhase 3 · HypertensionReliable signal | Dec 2026Sacituzumab Govitecan · Phase 3 |
 BiogenBIIB · Nasdaq | 17 assets: 9 approved, 3 Ph 3, 4 Ph 2, 1 Ph 1 | LitifilimabPhase 3 · Systemic Lupus ErythematosusReliable signal | 20 Oct 2026Litifilimab · Phase 2/3 |
 Ionis PharmaceuticalsIONS · Nasdaq | 17 assets: 6 approved, 5 Ph 3, 5 Ph 2, 1 Ph 1 | PelacarsenPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | Dec 2026Donidalorsen · Phase 3 |
 Arrowhead PharmaceuticalsARWR · Nasdaq | 16 assets: 1 approved, 3 Ph 3, 9 Ph 2, 3 Ph 1 | OlpasiranPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | Dec 2026SRP-1004 · Phase 1 |
 Vertex PharmaceuticalsVRTX · Nasdaq | 16 assets: 7 approved, 3 Ph 3, 5 Ph 2, 1 Ph 1 | PovetaciceptPhase 3 · Myasthenia Gravis | 30 Oct 2026Vanzacaftor / tezacaftor / deutivacaftor · Phase 3 |
 Alnylam PharmaceuticalsALNY · Nasdaq | 14 assets: 6 approved, 4 Ph 3, 3 Ph 2, 1 Ph 1 | ZilebesiranPhase 3 · HypertensionReliable signal | 12 Oct 2026Cemdisiran · Phase 3 |
 ViatrisVTRS · Nasdaq | 11 assets: 10 approved, 1 Ph 3 | sildenafilPhase 3 · HypertensionPartial signal | None on record |
 BioMarin PharmaceuticalBMRN · Nasdaq | 10 assets: 7 approved, 2 Ph 3, 1 Ph 2 | INZ-701Phase 3 · Chronic Kidney DiseaseWeak signal | 14 Oct 2026INZ-701 · Phase 1 |
 IncyteINCY · Nasdaq | 10 assets: 6 approved, 4 Ph 3 | INCA033989Phase 3 · Essential Thrombocythemia | 9 Oct 2026Ruxolitinib · Phase 3 |
 Amphastar Pharmaceuticals, Inc.AMPH · Nasdaq | 9 assets: 8 approved, 1 Ph 3 | albuterol sulfate (Amphastar)Phase 3 · AsthmaPartial signal | None on record |
 Supernus PharmaceuticalsSUPN · Nasdaq | 9 assets: 6 approved, 3 Ph 2 | SPN-817Phase 2 · EpilepsyWeak signal | 30 Dec 2026SPN-817 · Phase 1/2 |
 Jazz PharmaceuticalsJAZZ · Nasdaq | 8 assets: 6 approved, 2 Ph 3 | NabiximolsPhase 3 · Multiple SclerosisPartial signal | 31 Dec 2026Zanidatamab · Phase 2 |
 BeOne MedicinesONC · Nasdaq | 7 assets: 2 approved, 2 Ph 3, 1 Ph 2, 2 Ph 1 | BGB-11417Phase 3 · Chronic Lymphocytic Leukemia | Nov 2026BGB-11417 · Phase 2 |
 GenmabGMAB · Nasdaq | 7 assets: 3 approved, 1 Ph 3, 2 Ph 2, 1 Ph 1 | Rina-SPhase 3 · Ovarian Cancer | 31 Dec 2026Zenocutuzumab · Phase 2 |
 Alkermes plcALKS · Nasdaq | 6 assets: 5 approved, 1 Ph 3 | ALKS 2680Phase 3 · Narcolepsy | Nov 2026ALKS 2680 · Phase 2 |
 Axsome TherapeuticsAXSM · Nasdaq | 6 assets: 3 approved, 2 Ph 3, 1 Ph 2 | AXS-14Phase 3 · Fibromyalgia | Dec 2026Solriamfetol · Phase 3 |
 IDEAYA BiosciencesIDYA · Nasdaq | 6 assets: 1 Ph 3, 1 Ph 2, 4 Ph 1 | DarovasertibPhase 3 · Uveal Melanoma | 7 Jan 2027IDE397 · Phase 1 |
 MacroGenicsMGNX · Nasdaq | 6 assets: 1 approved, 1 Ph 2, 4 Ph 1 | LorigerlimabPhase 2 · Metastatic Castration-Resistant Prostate Cancer | Nov 2026MGD024 · Phase 1 |
 Neurocrine BiosciencesNBIX · Nasdaq | 6 assets: 2 approved, 3 Ph 3, 1 Ph 2 | NBI-1117568Phase 3 · SchizophreniaPartial signal | Jul 2027Osavampator · Phase 3 |
 Praxis Precision Medicines, Inc.PRAX · Nasdaq | 6 assets: 5 Ph 3, 1 Ph 2 | ElsunersenPhase 3 · Epilepsy | Dec 2026Vormatrigine · Phase 3 |
 Revolution MedicinesRVMD · Nasdaq | 6 assets: 1 approved, 1 Ph 3, 2 Ph 2, 2 Ph 1 | ZoldonrasibPhase 3 · Non-Small Cell Lung Cancer | 31 Dec 2026RMC-9805 · Phase 1 |
 XencorXNCR · Nasdaq | 6 assets: 2 Ph 2, 4 Ph 1 | XmAb5871Phase 2 · Systemic Lupus ErythematosusPartial signal | Feb 2027XmAb819 · Phase 1 |
 ANI Pharmaceuticals, Inc.ANIP · Nasdaq | 5 assets: 5 approved | Approved assets only | 18 Dec 2029Anastrozole · Phase 3 |
 CRISPR TherapeuticsCRSP · Nasdaq | 5 assets: 1 approved, 3 Ph 2, 1 Ph 1 | SRSD107Phase 2 · Atherosclerotic Cardiovascular Disease | Jun 2027CTX310 · Phase 1 |
 Iovance BiotherapeuticsIOVA · Nasdaq | 5 assets: 2 approved, 3 Ph 2 | LN-145Phase 2 · Non-Small Cell Lung CancerWeak signal | Sep 2027IOV-4001 · Phase 1/2 |
 Tonix PharmaceuticalsTNXP · Nasdaq | 5 assets: 3 approved, 2 Ph 2 | TNX-1300Phase 2 · Cocaine Intoxication | Feb 2028cyclobenzaprine · Phase 2 |
 Vanda PharmaceuticalsVNDA · Nasdaq | 5 assets: 4 approved, 1 Ph 3 | tradipitantPhase 3 · Gastroparesis | 1 Dec 2026tradipitant · Phase 3 |
 AC ImmuneACIU · Nasdaq | 4 assets: 4 Ph 2 | AFFITOPE PD01A / ACI-7104.056Phase 2 · Parkinson's Disease | 22 Dec 2026JNJ-64042056 · Phase 2 |
 Acadia PharmaceuticalsACAD · Nasdaq | 4 assets: 2 approved, 1 Ph 3, 1 Ph 2 | ACP-204Phase 3 · Alzheimer's Disease | Aug 2027ACP-211 · Phase 2 |
 Arcus BiosciencesRCUS · Nasdaq | 4 assets: 2 Ph 3, 2 Ph 1 | CasdatifanPhase 3 · Clear Cell Renal Cell Carcinoma | Nov 2026AB801 · Phase 1 |
 Corcept TherapeuticsCORT · Nasdaq | 4 assets: 2 approved, 2 Ph 2 | miricorilantPhase 2 · MASH / NASHWeak signal | 30 Oct 2026miricorilant · Phase 1 |
 CytokineticsCYTK · Nasdaq | 4 assets: 1 approved, 2 Ph 3, 1 other | Omecamtiv mecarbilPhase 3 · Heart FailureReliable signal | Sep 2027Omecamtiv mecarbil · Phase 3 |
 Denali TherapeuticsDNLI · Nasdaq | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | BIIB122 / DNL151 (LRRK2 inhibitor)Phase 3 · Parkinson's DiseasePartial signal | Feb 2027DNL628 · Phase 1 |
 Faeth Therapeutics, Inc.FTH · Nasdaq | 4 assets: 3 Ph 2, 1 other | SapanisertibPhase 2 · HR+/HER2- Metastatic Breast CancerWeak signal | Sep 2028Serabelisib · Phase 2 |
 Fate TherapeuticsFATE · Nasdaq | 4 assets: 2 Ph 2, 2 Ph 1 | FT819Phase 2 · Systemic Lupus Erythematosus | 30 Sep 2027FT819 · Phase 1 |
 Harrow, Inc.HROW · Nasdaq | 4 assets: 4 approved | Approved assets only | 4 Feb 2027Ranibizumab · Phase 3 |
 Kodiak Sciences Inc.KOD · Nasdaq | 4 assets: 4 Ph 3 | KSI-301Phase 3 · Age-Related Macular DegenerationReliable signal | Feb 2027KSI-101 · Phase 3 |
 ModernaMRNA · Nasdaq | 4 assets: 2 approved, 1 Ph 3, 1 Ph 2 | Intismeran AutogenePhase 3 · Non-Small Cell Lung Cancer | 31 Dec 2026elasomeran · Approved |
 REGENXBIO Inc.RGNX · Nasdaq | 4 assets: 4 Ph 3 | RGX-314Phase 3 · Age-Related Macular DegenerationWeak signal | Dec 2026Surabgene Lomparvovec (ABBV-RGX-314) · Phase 2/3 |
 Radiopharm Theranostics, LtdRADX · Nasdaq | 4 assets: 1 Ph 2, 1 Ph 1, 2 other | 177Lu-BetaBartPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2027177Lu-RAD204 · Phase 1 |
 Rhythm PharmaceuticalsRYTM · Nasdaq | 4 assets: 1 approved, 3 Ph 2 | LB54640Phase 2 · ObesityPartial signal | 31 Oct 2026setmelanotide · Phase 2 |
 Spyre TherapeuticsSYRE · Nasdaq | 4 assets: 4 Ph 2 | SPY001Phase 2 · Ulcerative Colitis | 31 Oct 2026SPY072 · Phase 2 |
 Tango TherapeuticsTNGX · Nasdaq | 4 assets: 4 Ph 2 | TNG260Phase 1/2 · Non-Small Cell Lung Cancer | 31 Mar 2027TNG456 · Phase 1/2 |
 Wave Life SciencesWVE · Nasdaq | 4 assets: 4 Ph 2 | WVE-003Phase 1/2 · Huntington's Disease | Dec 2027WVE-007 · Phase 1/2 |
 Zai LabZLAB · Nasdaq | 4 assets: 2 approved, 1 Ph 2, 1 Ph 1 | ZL-1102Phase 2 · PsoriasisPartial signal | 26 Nov 2026Niraparib · Phase 3 |
 AlectorALEC · Nasdaq | 3 assets: 2 Ph 2, 1 other | AL002Phase 2 · Alzheimer's Disease | 15 Sep 2028GSK4527226 (AL101) · Phase 2 |
 Annexon, Inc.ANNX · Nasdaq | 3 assets: 3 Ph 3 | ANX007Phase 3 · Age-Related Macular DegenerationPartial signal | 31 Oct 2026ANX007 · Phase 3 |
 Aquestive Therapeutics, Inc.AQST · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 other | Diazepam (Libervant)Phase 3 · EpilepsyWeak signal | None on record |
 Beam Therapeutics Inc.BEAM · Nasdaq | 3 assets: 2 Ph 2, 1 other | BEAM-301Phase 1/2 · Glycogen Storage Disease Type Ia | 30 Dec 2027BEAM-301 · Phase 1/2 |
 BioNTechBNTX · Nasdaq | 3 assets: 1 Ph 2, 2 Ph 1 | BNT116Phase 2 · Non-Small Cell Lung Cancer | Nov 2026BNT351 · Phase 1 |
 Biomea FusionBMEA · Nasdaq | 3 assets: 1 Ph 2, 2 Ph 1 | BMF-219Phase 2 · Type 2 DiabetesPartial signal | Mar 2027BMF-219 · Phase 2 |
 Caribou Biosciences, Inc.CRBU · Nasdaq | 3 assets: 3 Ph 1 | CB-010Phase 1 · B-Cell Non-Hodgkin Lymphoma | Dec 2027CB-011 · Phase 1 |
 Cogent Biosciences, Inc.COGT · Nasdaq | 3 assets: 1 Ph 3, 2 Ph 1 | bezuclastinibPhase 3 · Gastrointestinal Stromal Tumor | May 2028CGT4255 · Phase 1 |
| 3 assets: 3 approved | Approved assets only | None on record | |
 Corvus PharmaceuticalsCRVS · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 2 | soquelitinibPhase 3 · Peripheral T-Cell LymphomaPartial signal | Jun 2027soquelitinib · Phase 2 |
 Disc MedicineIRON · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | BitopertinPhase 3 · Erythropoietic Protoporphyria | May 2027DISC-0974 · Phase 1/2 |
 ExelixisEXEL · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 Ph 1 | ZanzalintinibPhase 3 · Clear Cell Renal Cell Carcinoma | 23 Nov 2026XB010 · Phase 1 |
 Indivior Pharmaceuticals, Inc.INDV · Nasdaq | 3 assets: 3 approved | Approved assets only | None on record |
 Kura Oncology, Inc.KURA · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 1 | TipifarnibPhase 3 · Clear Cell Renal Cell Carcinoma | Dec 2026Ziftomenib · Phase 1 |
 Ligand PharmaceuticalsLGND · Nasdaq | 3 assets: 3 approved | Approved assets only | 1 Mar 2027ensifentrine · Phase 2 |
 Madrigal PharmaceuticalsMDGL · Nasdaq | 3 assets: 1 approved, 1 Ph 2, 1 other | PF-06865571Phase 2 · MASH / NASHPartial signal | Dec 2026Resmetirom · Phase 3 |
 MannKind CorporationMNKD · Nasdaq | 3 assets: 3 approved | Approved assets only | Mar 2027Afrezza · Phase 2 |
 MesoblastMESO · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | rexlemestrocel-LPhase 3 · Heart Failure | Jul 2027rexlemestrocel-L · Phase 3 |
 OCULAR THERAPEUTIX, INCOCUL · Nasdaq | 3 assets: 1 approved, 2 Ph 3 | OTX-TKIPhase 3 · Age-Related Macular Degeneration | 8 Jan 2027OTX-TKI · Phase 3 |
 OPKO HealthOPK · Nasdaq | 3 assets: 2 approved, 1 Ph 2 | OPK-88006Phase 1/2 · MASH / NASH | Oct 2027Extended-release calcifediol · Phase 2 |
 ORIC PharmaceuticalsORIC · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | ORIC-944Phase 3 · Prostate Cancer | Dec 2026ORIC-114 · Phase 1 |
 PTC TherapeuticsPTCT · Nasdaq | 3 assets: 2 approved, 1 Ph 3 | Vatiquinone (PTC743)Phase 3 · Friedreich Ataxia | 31 Dec 2027Vatiquinone (PTC743) · Phase 3 |
 Prothena Biosciences LimitedPRTA · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 other | PrasinezumabPhase 3 · Parkinson's Disease | 30 Jun 2029Prasinezumab · Phase 3 |
 Replimune, Inc.REPL · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | RP2Phase 2/3 · Solid Tumors | 31 Oct 2026RP2 · Phase 1 |
 Roivant Sciences Ltd.ROIV · Nasdaq | 3 assets: 1 approved, 2 Ph 3 | IMVT-1402Phase 3 · Myasthenia Gravis | Dec 2026Mosliciguat · Phase 2 |
 Stoke Therapeutics, Inc.STOK · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 other | ZorevunersenPhase 3 · Dravet Syndrome | Mar 2027Zorevunersen · Phase 3 |
 Sutro Biopharma, Inc.STRO · Nasdaq | 3 assets: 1 Ph 3, 2 Ph 1 | luveltamab tazevibulinPhase 2/3 · Ovarian Cancer | Dec 2027STRO-004 · Phase 1 |
 TG THERAPEUTICS, INC.TGTX · Nasdaq | 3 assets: 1 approved, 2 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 31 Oct 2026Ublituximab · Phase 3 |
| 3 assets: 3 Ph 1 | BBO-10203Phase 1 · Non-Small Cell Lung Cancer | Aug 2027BBO-10203 · Phase 1 | |
 United TherapeuticsUTHR · Nasdaq | 3 assets: 2 approved, 1 Ph 3 | RalinepagPhase 3 · HypertensionReliable signal | Dec 2026Ralinepag · Phase 3 |
 Verastem, Inc.VSTM · Nasdaq | 3 assets: 2 approved, 1 Ph 2 | VS-7375Phase 2 · Non-Small Cell Lung Cancer | Jun 2027VS-7375 · Phase 2 |
 Viking TherapeuticsVKTX · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | VK2735Phase 3 · ObesityReliable signal | 1 Jul 2027VK2735 · Phase 3 |
 VistaGen TherapeuticsVTGN · Nasdaq | 3 assets: 2 Ph 3, 1 other | AV-101Phase 3 · Major Depressive DisorderPartial signal | None on record |
 ZymeworksZYME · Nasdaq | 3 assets: 2 approved, 1 Ph 3 | Ampreloxetine (TD-9855)Phase 3 · Neurogenic Orthostatic HypotensionPartial signal | 31 Dec 2026Zanidatamab · Phase 2 |
 uniQureQURE · Nasdaq | 3 assets: 1 approved, 2 Ph 2 | AMT-130Phase 1/2 · Huntington's Disease | 30 Nov 2026AMT-260 · Phase 1/2 |
 vTv TherapeuticsVTVT · Nasdaq | 3 assets: 1 Ph 3, 2 Ph 2 | cadisegliatinPhase 3 · Type 1 Diabetes | Apr 2027cadisegliatin · Phase 3 |
 ALX Oncology Inc.ALXO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | EvorpaceptPhase 2/3 · Gastric Cancer | Jun 2027ALX2004 · Phase 1 |
 Adlai Nortye Biopharma Co., Ltd.ANL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | BuparlisibPhase 3 · Head and Neck Squamous Cell Carcinoma | None on record |
 Akebia TherapeuticsAKBA · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | PraliciguatPhase 2 · Chronic Kidney Disease | Jun 2027Praliciguat · Phase 2 |
 Allogene Therapeutics, Inc.ALLO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | cemacabtagene ansegedleucelPhase 2 · Large B-Cell Lymphoma | Dec 2027cemacabtagene ansegedleucel · Phase 2 |
 AlphaTON Capital Corp.ATON · Nasdaq | 2 assets: 2 Ph 2 | TT-10Phase 1/2 · Non-Small Cell Lung Cancer | 1 Dec 2028TT-10 · Phase 1/2 |
 AlumisALMS · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | EnvudeucitinibPhase 3 · PsoriasisReliable signal | 1 Dec 2027Envudeucitinib · Phase 2 |
 AlvotechALVO · Nasdaq | 2 assets: 2 approved | Approved assets only | None on record |
 Anavex Life SciencesAVXL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | BlarcamesinePhase 3 · Alzheimer's DiseaseReliable signal | None on record |
 Apollomics Inc.APLM · Nasdaq | 2 assets: 2 Ph 3 | UproleselanPhase 3 · Relapsed/Refractory Acute Myeloid Leukemia | None on record |
 Aptevo TherapeuticsAPVO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | ALG.APV-527Phase 1/2 · Solid Tumors | Oct 2027APVO436 · Phase 1 |
 Ascendis Pharma Oncology Division A/SASND · Nasdaq | 2 assets: 2 approved | Approved assets only | None on record |
 Aurinia PharmaceuticalsAUPH · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | aritinerceptPhase 1/2 · Systemic Lupus Erythematosus | 2 Mar 2029Voclosporin · Approved |
 Avalo Therapeutics, Inc.AVTX · Nasdaq | 2 assets: 2 Ph 2 | AVTX-002Phase 2 · AsthmaPartial signal | None on record |
 BicycleTx LimitedBCYC · Nasdaq | 2 assets: 2 Ph 2 | Zelenectide pevedotinPhase 2 · Non-Small Cell Lung Cancer | Mar 2028Zelenectide pevedotin · Phase 2 |
 COMPUGEN LTDCGEN · Nasdaq | 2 assets: 2 Ph 1 | COM902Phase 1 · Multiple MyelomaWeak signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).